ZA922527B - Remedies for bone diseases - Google Patents

Remedies for bone diseases

Info

Publication number
ZA922527B
ZA922527B ZA922527A ZA922527A ZA922527B ZA 922527 B ZA922527 B ZA 922527B ZA 922527 A ZA922527 A ZA 922527A ZA 922527 A ZA922527 A ZA 922527A ZA 922527 B ZA922527 B ZA 922527B
Authority
ZA
South Africa
Prior art keywords
remedies
bone diseases
bone
diseases
droloxifene
Prior art date
Application number
ZA922527A
Other languages
English (en)
Inventor
Kazuaki Niikura
Niikura Kazuaki
Yoshimitsu Nakajima
Nakajima Yoshimitsu
Yoshitada Notsu
Notsu Yoshitada
Ryuji Ono
Ono Ryuji
Osamu Nakayama
Nakayama Osamu
Original Assignee
Klinge Co Chem Pharm Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinge Co Chem Pharm Fab filed Critical Klinge Co Chem Pharm Fab
Publication of ZA922527B publication Critical patent/ZA922527B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA922527A 1991-04-09 1992-04-08 Remedies for bone diseases ZA922527B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3166944A JPH04312526A (ja) 1991-04-09 1991-04-09 骨疾患治療剤

Publications (1)

Publication Number Publication Date
ZA922527B true ZA922527B (en) 1992-12-30

Family

ID=15840531

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA922527A ZA922527B (en) 1991-04-09 1992-04-08 Remedies for bone diseases

Country Status (13)

Country Link
US (1) US5254594A (de)
EP (1) EP0509317B1 (de)
JP (1) JPH04312526A (de)
KR (1) KR100196810B1 (de)
AT (1) ATE114113T1 (de)
AU (1) AU648154B2 (de)
CA (1) CA2065093C (de)
DE (1) DE69200675T2 (de)
DK (1) DK0509317T3 (de)
EE (1) EE02971B1 (de)
ES (1) ES2064130T3 (de)
IE (1) IE66900B1 (de)
ZA (1) ZA922527B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5886049A (en) * 1992-10-27 1999-03-23 Nippon Kayaku Kabushiki Kaisha Remedy for autoimmune diseases
EP0667768B1 (de) 1992-10-27 1999-03-03 Nippon Kayaku Kabushiki Kaisha Verwendung von toremifene für die behandlung von sle
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE4401554A1 (de) * 1993-02-16 1994-08-18 Freund Andreas Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
ES2105525T3 (es) * 1993-06-24 1997-10-16 Lilly Co Eli 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
TW398975B (en) 1994-07-22 2000-07-21 Lilly Co Eli Pharmaceutical composition for inhibiting bone loss
US5489587A (en) * 1995-01-20 1996-02-06 Eli Lilly And Company Benzofurans used to inhibit bone loss
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
US5719190A (en) * 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US5726207A (en) * 1996-02-28 1998-03-10 Pfizer Inc. Protection of ischemic myocardium against reperfusion damage
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US5985932A (en) * 1996-02-28 1999-11-16 Pfizer Inc Inhibition of autoimmune diseases
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
IL120269A0 (en) * 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
US5733937A (en) * 1996-02-28 1998-03-31 Pfizer Inc. Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
US6110942A (en) * 1996-06-17 2000-08-29 Eli Lilly And Company Method for minimizing the uterotrophic effect of droloxifene
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
US5792798A (en) * 1996-07-29 1998-08-11 Eli Lilly And Company Method for inhibiting plasminogen activator inhibitor 1
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6114395A (en) * 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
EP0897720A1 (de) * 1997-08-13 1999-02-24 Pfizer Products Inc. Verwendung von droloxifen zur vorbeugung von mammakarzinom
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
EP1253966B1 (de) * 1999-08-13 2011-04-27 Curadis GmbH Substanzen und mittel zur positiven beeinflussung von kollagen
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US9050368B2 (en) * 2007-11-13 2015-06-09 Meritage Pharma, Inc. Corticosteroid compositions
HUE038452T2 (hu) 2007-11-13 2018-10-29 Meritage Pharma Inc Gyomor és bélrendszeri gyulladások kezelésére szolgáló kompozíciók

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002097B1 (de) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalken-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
US4206234A (en) * 1977-08-22 1980-06-03 Imperial Chemical Industries Limited Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency

Also Published As

Publication number Publication date
IE66900B1 (en) 1996-02-07
CA2065093C (en) 1995-10-03
DE69200675D1 (de) 1994-12-22
CA2065093A1 (en) 1992-10-10
ES2064130T3 (es) 1995-01-16
KR920019342A (ko) 1992-11-19
HK1004257A1 (en) 1998-11-20
IE921116A1 (en) 1992-10-21
AU648154B2 (en) 1994-04-14
EP0509317A2 (de) 1992-10-21
DK0509317T3 (da) 1995-01-30
ATE114113T1 (de) 1994-12-15
DE69200675T2 (de) 1995-03-16
EP0509317B1 (de) 1994-11-17
AU1399492A (en) 1992-10-15
US5254594A (en) 1993-10-19
EP0509317A3 (en) 1993-03-03
EE02971B1 (et) 1997-04-15
JPH04312526A (ja) 1992-11-04
KR100196810B1 (ko) 1999-06-15

Similar Documents

Publication Publication Date Title
AU1399492A (en) Remedies for bone diseases
AU2807195A (en) Hair growing agent
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
EP1468679A3 (de) Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe
PL299814A1 (en) Pharmaceutical preparation inhibiting depletion of human bone tissue
ZA927305B (en) Substituted 4-akoxypyrimidines, process for their preparation, agents containing them, and their use as pesticides.
TW234691B (de)
HUT68241A (en) Herbicidal compositions with increased crop safety, containing sulfonamide or sulfonylurea as activ ingredient
IL105577A (en) Fungicidal compositions containing 3-hydroxy- 5-methylisoxazole or salts thereof, methods for the preparation thereof and their use
AU1945495A (en) Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
GB9410817D0 (en) Medicaments
EP0586812A3 (de) Arzneimittel die Glicentin als aktiven Wirkstoff enthalten.
AU3927689A (en) Antimicrobial agent for animals
ZA9244B (en) Antidepressant
IL104156A0 (en) Fungicidal compositions containing certain compounds,their agricultural use and methods for producing said compounds
GR3037039T3 (en) Use of trimetazidine for the preparation of medicaments for the treatment of troubles due to the therapeutical use of immunosuppressants.
EP0880966A4 (de) Thiamindisulfide und diese als wirkstoff enthaltende medikamente
UA12937A (uk) Засіб для локальhого лікуваhhя гhійhо-запальhих раh та опіків, іhфіковаhих стафілококом
ES1023843Y (es) Zapatilla quirurgica para animales.
ITTO920656A1 (it) Sedia per operativita' chirurgica.
IE893198L (en) Treatment for diseases caused by retroviruses
AU117366S (en) Surgical shoes for animals
ZA878195B (en) Biocidal,particularly virucidal,compositions
FR2532847B1 (fr) Composition pharmaceutique comprenant a titre de principe actif le 3,7,11,15-tetramethylhexadeca-1-ene-3-ol
UA27784C2 (uk) Шипуча фармацевтична композиція для орального введення